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Abstract: β-Glucan is a natural polymer, which is widely studied due to its multiple immunomodulatory properties. In addition, recent
findings indicate potent antitumor properties of β-glucan. Saccharomyces cerevisiae, baker’s yeast, is one of the commonly used sources
of β-1,3-glucan. The aim of this work was to investigate S. cerevisiae β-glucan immunomodulatory activity against cancer cells. In our
experiments, BALB/c mice were fed with insoluble whole β-glucan particles, and then their blood was collected for experiments. MH22a hepatoma cells were treated with the blood of mice fed with β-glucan, and tumor cell viability was investigated after the treatment.
The obtained results demonstrated that leukocytes in vivo primed with whole glucan particles, in combination with soluble β-glucan,
decreased MH-22a hepatoma cell viability in vitro. Our study has indicated that β-glucan obtained from S. cerevisiae potentially primes
mouse whole blood leukocytes to induce cell death of mouse hepatoma cells.
Key words: β-Glucan, yeast, cancer, mice

1. Introduction
β-Glucan is a natural polymer made of glucose monomers
linked by β-glycosidic bonds. It is produced by various
organisms including bacteria, fungi, and plants. β-Glucan
polymer modifications in a variety of organisms result in
differences in their glycosidic linkage position, structure,
and complexity, e.g., bacterial β-1-3-glucan curdlan has a
linear structure and is insoluble in water, whereas cereal
β-glucans often are β-1-3,1-4-glucans and the majority of
them are water soluble (Basic et al., 2008). β-Glucans are
widely studied due to their multiple immunomodulatory
properties (Mantovani et al., 2008). β-1,3-Glucans, in
particular, have demonstrated a significant physiological
effect on the mammalian immune system with their ability
to activate leukocytes and trigger the immune response
(Chen et al., 2008; Novak and Vetvicka, 2008; PetravićTominac et al., 2010; Marakalala et al., 2013). β-Glucans
can be used in the treatment of fungal, bacterial, viral,
and protozoal infections and to increase immune system
cytotoxicity against tumor cells (Chen et al., 2008; Novak
and Vetvicka, 2008; Chan et al., 2009; Javmen et al.,
2013a, 2013b). It is important to note that highly purified
β-glucans are characterized by very low toxicity (e.g.,
mouse lentinan has LD50 > 1600 mg/kg) (Novak and
Vetvicka, 2009).
* Correspondence: arturas.biocentras@gmail.com
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One of the commonly used sources of β-1,3-glucan is
Saccharomyces cerevisiae, baker’s yeast (Hunter et al., 2002;
Pelizon et al., 2005; Shokri et al., 2008; Novak and Vetvicka,
2009; Vetvicka, 2011; Javmen et al., 2012; Javmen et al.,
2013b). β-1,3-Glucan is a major component (50%–55%) of
S. cerevisiae cell walls (Lee et al., 2000; Shokri et al., 2008).
Yeast glucan has been shown to help maintain the rigidity
and shape of the cell (Petravić-Tominac et al., 2010). Recent
studies have also indicated that yeast cell wall β-glucan,
either soluble or particulate, can exhibit antimicrobial and
antitumor effects (Shokri et al., 2008; Chan et al., 2009).
It is thought that β-glucan can be used as a safe, effective,
therapeutic, and/or prophylactic agent, either alone or as
adjuvant, to enhance the immune response in mammals
with normal or decreased immunological function (Shokri
et al., 2008).
As mentioned previously, recent findings indicate
potent antitumor properties of β-glucan (Chan et al.,
2009; Vetvicka, 2011). On the other hand, the molecular
mechanisms that underlie these responses are not
completely understood (Budak et al., 2008; Chan et al.,
2009). The above data were obtained using both soluble and
insoluble β-glucan (Li et al., 2006). The similarities in results
obtained using different β-glucans might be explained by
the fact that orally administrated β-glucans (animal data)
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enter the proximal small intestine and are “captured” by
the macrophages. Subsequently, macrophages internalize
and hydrolyze β-glucan molecules into small fragments,
which are later carried to the marrow, and thus immune
response is elicited (Chan et al., 2009).
The results of our current study indicate that β-glucan
obtained from S. cerevisiae can prime mouse blood
leukocytes for cytotoxicity against MH-22a mouse
hepatoma cells. In these experiments, BALB/c mice were
fed with insoluble whole β-glucan particles for 1 week and
their blood was collected for experiments. MH-22a cells
were grown in 24-well plates for 24 h and treated with the
blood of mice fed with β-glucan (diluted in cell culture
medium). Soluble β-glucan was also added to the cell
culture medium. The obtained results demonstrate that
leukocytes in vivo primed with whole glucan particles,
in combination with soluble β-glucan, decrease MH-22a
hepatoma cell viability in vitro.
2. Materials and methods
2.1. Chemicals
All experiments were performed using reagent-grade
materials. Insoluble S. cerevisiae cell wall whole β-glucan
particles were extracted according to the method
published by Javmen et al. (2012) with some modifications.
Briefly, 3 g of dry baker’s yeast was enzymatically lysed by
Streptomyces rutgersensis yeast lysing complex and washed
with distilled water. Yeast cell walls were isolated by
centrifugation and resuspended in NaOH solution (1 M)
using a 1 g:5 mL ratio. The mixture was heated for 2 h at
100 °C with stirring. Whole glucan particles were harvested
by centrifugation and washed with distilled water until
neutral pH was achieved. Soluble β-glucan (molecules
of about 0.7–23 nm) was produced by enzymatic whole
glucan particle hydrolysis using S. rutgersensis β-glucanase
(Javmen et al., 2013a).
2.2. Experimental animals
Mice (8-week-old males, with a body weight of 20–24
g) were kindly donated by the animal facility of the
State Research Institute Centre for Innovative Medicine.
Experimental conditions were in compliance with
regulatory laboratory practices and followed the Law
of the Republic of Lithuania on the Care, Maintenance,
and Use of Animals as well as secondary legislation, the
Order of the State Food and Veterinary Service of the
Republic of Lithuania “On Veterinary Regulations on
Breeding, Handling, and Transportation of Laboratory
Animals” and “On the Use of Laboratory Animals in
Scientific Experiments” (Law of the Care, Welfare, and
Use of Animals, 2002). The protocol was approved by the
State Food and Veterinary Service/Ethical Committee for
Animal Research (protocol No. 0202, 2009). The animals
were acclimatized for 1 week prior to the study. They were

housed maintaining and monitoring the temperature,
humidity, and light/dark cycle (12 h/12 h). A commercial
pellet diet and fresh drinking water were provided ad
libitum.
Experimental mice (n = 12) were orally fed 0.1 mL
water containing 0.1 mg of insoluble β-glucan particles
daily for a period of 2 weeks. The above animals were
sacrificed, and 100 µL of blood was taken from Jung’s vein
after administration of β-glucan. The blood samples (0.1
mL) were mixed with 0.9 mL of Dulbecco’s modified Eagle
medium (DMEM) containing 10% fetal bovine serum, and
50 µg of the soluble β-glucan was added. These solutions
were used for in vitro experimentation. The remaining 12
mice were fed a regular diet as a control.
2.3. Tumor cell line
The cell line of the murine hepatoma MH-22a was obtained
from the Institute of Cytology, Russian Federation. The
cultivation of the hepatoma cells was carried out under
standard conditions: cells were grown in monolayer in
the cell culture flasks in DMEM containing 10% fetal
bovine serum and antibiotics at 37 °C (Shvenberger and
Alexandrova, 2000; Grellier et al., 2008; Obakan et al.,
2014).
2.4. Whole mouse blood leukocytes
Whole mouse blood was stained with acridine orange in
conjunction with ethidium bromide on microscopic glass
slides (Nemeikaitė-Čėnienė et al., 2005). The leukocyte
count and type (morphological appearance) were
determined using a fluorescent microscope (Leica DMLB).
The experiment was repeated 12 times using different mice
(1 blood smear from each).
2.5. Hepatoma cell treatment
MH-22a cells were grown in a 24-well plate (1 × 105/mL)
and incubated in DMEM for 24 h. Subsequently, MH-22a
cells were treated with 1 mL of DMEM containing one of
the following:
1) 50 µg of soluble β-glucan and 0.1% (v/v) whole blood
obtained from mice fed with β-glucan,
2) 0.1% (v/v) whole blood obtained from mice fed with
β-glucan,
3) 50 µg of the soluble β-glucan and 0.1% (v/v) whole
blood obtained from control mice (normal diet), or
4) 50 µg of the soluble β-glucan.
As a control, MH-22a cells without any treatment or
treated with 1 mL of DMEM containing 0.1% (v/v) whole
blood obtained from mice fed a normal diet were used. The
viability of the cells was examined after 24 h of incubation
after the treatment (Nemeikaitė-Čėnienė et al., 2005). All
experiments were repeated 6 times.
2.6. Tumor cell viability
Acridine orange in conjunction with ethidium bromide
staining of MH-22a cells on glass slides was used to
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differentiate between viable and dead cells (NemeikaitėČėnienė et al., 2005; Prabhu et al., 2014). The number of
viable and dead cells was determined using fluorescent
microscopy (Leica DMLB).
2.7. Statistical analysis
The significance of differences between means was assessed
using Student’s t-test.
3. Results
Insoluble β-glucan from Saccharomyces cerevisiae (baker’s
yeast) was extracted and hydrolyzed using β-glucanase
from Streptomyces rutgersensis as previously described by
Javmen et al. (2013a) (Figure 1).
Next, mice were fed with the insoluble β-glucan for
1 week. Subsequently, mouse whole blood was collected,
and the leukocyte count of mice fed with β-glucan was
analyzed and compared to the blood leukocyte count of
the control group.
As shown in Figure 2, feeding mice with insoluble
β-glucan induced an increase in the neutrophil blood count
and a concomitant decrease in lymphocyte count, while
the numbers of basophilic, eosinophilic, and monocytic
leukocytes were unchanged.
1

2

3

Figure 1. Thick layer chromatography of reaction products after
S. cerevisiae cell wall β-glucan hydrolysis. 1) Glucose (20 µg), 2)
sucrose (20 µg), 3) insoluble β-glucan hydrolysis products (100
µg). Solvent system: ethyl acetate-methanol-water, 52:36:13 by
volume; staining: 10% sulfuric acid solution diluted with ethanol
(Javmen et al., 2013b).
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Mice fed with β-glucan

Figure 2. Blood leukocyte count of the control mice and mice
treated with the insoluble β-glucan preparation. Each value
represents the middle point of 12 replicates with the standard
margin of error. *: P < 0.05.

In the next series of experiments, MH-22a hepatoma
cells were incubated under the various experimental
conditions described in Section 2 and MH-22a cell
viability was analyzed 24 h later.
The results of our experiments indicate that the
number of dead MH-22a cells is higher after treatment
with the blood of mice fed with β-glucan in combination
with soluble β-glucan as opposed to all other conditions,
including the control (Figure 3). The dead cell count was
between 2% and 4% in all of the experiments, except
when MH-22a cells were treated with the blood obtained
from mice fed with β-glucan in combination with soluble
β-glucan (>10% dead cells) (Figure 3).
The increase in cell death (Figure 3) was correlated
with a concomitant decrease in the number of adherent
cells under the experimental conditions employed (Figure
4). Furthermore, it was determined that the total adherent
cell count was the lowest after treatment with the blood
of mice fed with β-glucan in combination with treatment
with soluble β-glucan (Figure 4). Adherent cell count in the
latter was about 63.5%, in comparison to the untreated cell
count. In all other experiments, the adherent cell count was
about 75%–85%. In the experiments with soluble β-glucan
only, adherent cell count was about 97.6% compared to the
untreated cells (Figure 4).
4. Discussion
β-Glucan in Saccharomyces cerevisiae (baker’s yeast) is
considered a mammalian immune system stimulator,
and, as mentioned previously, can be helpful in treating
infectious diseases and cancer (Vetvicka, 2011).
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Blood (mice fed with β-glucan) + soluble β-glucan
Blood (mice fed with β-glucan)
Blood (normally fed mice) + soluble β-glucan
Blood (normally fed mice)
Soluble β-glucan
Normal cells without any treatment

Blood (mice fed with β-glucan) + soluble β-glucan
Blood (mice fed with β-glucan)
Blood (normally fed mice) + soluble β-glucan
Blood (normally fed mice)
Soluble β-glucan
Normal cells without any treatment

Figure 3. MH-22a cell viability. MH-22a cells were challenged
under various conditions described in Section 2 and assessed
for cell viability using acridine/ethidium bromide staining. The
results are presented as percentage of dead cells. Each value
represents the middle point of 6 replicates with the standard
margin of error.

Figure 4. MH-22a cell viability. Total number of MH-22a cells
after different treatments. Each value represents the middle point
of 6 replicates with the standard error. *: P < 0.05 represents a
significant difference between control mice and mice treated
with β-glucan preparations.

In the current study, we investigated whether
Saccharomyces cerevisiae β-glucan primes mouse blood
leukocytes for cytotoxicity against MH-22a mouse
hepatoma cells. Our results indicate that hepatoma cell
treatment with 0.1% (v/v) blood of mice fed with β-glucan
particles, in combination with soluble β-glucan, induces
MH-22a cell death in vitro. In addition, oral β-glucan
administration changes blood leukocyte composition in
BALB/c mice, i.e. it increases the neutrophil count and
decreases the number of lymphocytes.
Although the antitumor properties of β-glucan are well
established, the mechanisms involving its impact on cancer
cells have not been fully investigated (Budak et al., 2008; Chan
et al., 2009; Vetvicka, 2011). β-Glucans per se have no direct
effect on tumor cells (Li et al., 2006; Chan et al., 2009). One
hypothesis is that β-glucan induces the effector mechanism of
complement receptor 3 (CR3)-dependent cellular cytotoxicity
(DCC). According to this mechanism, leukocyte CR3
receptors do not trigger the death of tumor cells coated with
their ligands, C3b and iC3b. However, there has been much
evidence suggesting that leukocyte CR3 receptors can be
manipulated to trigger cytotoxicity of cells coated with iC3b.
The CR3-DCC mechanism is normally used by an organism
to eradicate yeast and fungi cells. The induction of CR3-DCC
requires dual ligation of CR3 to iC3b and β-glucan (the main
cell wall component in yeast and fungi). Since cancer cells

do not contain β-glucan on their surface, they cannot trigger
the CR3-DCC mechanism, even though they are coated with
iC3b. Therefore, our findings suggest that tumor cells can
potentially be eradicated through the CR3-DCC mechanism
when soluble β-glucan is added to the medium. To this end,
β-glucan primes the CR3 receptor to trigger cytotoxicity of
cells coated with iC3b but lacking β-glucan (Gelderman et al.,
2004; Li et al., 2007). It is also hypothesized that the CR3DCC effectors mentioned above are actually neutrophil cells
(Li et al., 2007; Driscoll et al., 2009).
Our data also confirm the previous finding that
β-glucan, per se, has no effect on cell viability as assessed
by the MH-22a viability assay (Figures 3 and 4). On the
contrary, incubation of cells with mouse blood decreased
MH-22a cell viability, although the observed changes
did not reach statistical significance (Figure 3). On the
other hand, all MH-22a cell treatments with mouse blood
decreased the total number of adherent cells in the culture
dish (Figure 4). The latter can be interpreted as follows:
cells die and detach, and therefore the total adherent cell
count decreases.
These findings are in agreement with existing
experimental results, demonstrating that soluble β-glucan
is necessary to prime leukocytes for cancer cell eradication
(Li et al., 2007; Driscoll et al., 2009). However, a single
MH-22a treatment with soluble β-glucan and mouse
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blood was not enough to induce hepatoma cell death.
We also needed mouse immune system activation with
the particulate β-glucan. This fact can be interpreted as
follows: the composition of the blood leukocytes changed
after administration of β-glucan particles to the mice; as a
result, we observed the increment of neutrophils, which
are effector cells in the CR3-DCC mechanism.

In summary, the data obtained in this study demonstrate
that β-glucan in Saccharomyces cerevisiae has no direct
effect on MH-22a hepatoma tumor cells, but it potentially
primes mouse whole blood leukocytes (neutrophils) to
induce MH-22a death. The exact molecular mechanisms
of the observed phenomenon remain to be determined.
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